Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
O. Kanai (Kyoto, Japan), K. Fujita (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Horimoto (Kyoto, Japan), M. Hashimoto (Kyoto, Japan), K. Nakatani (Kyoto, Japan), S. Sawai (Kyoto, Japan), T. Mio (Kyoto, Japan). Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study. 1658

Member's Comments

No comment yet.

Related content which might interest you: The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Tolerance to COX-2 inhibitors in patients intolerant to aspirin: challenge mandatory Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003 Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020 Year: 2021 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Roles of PI3k pan-inhibitors and PI3k-d inhibitors in allergic lung inflammation: systematic review and a meta-analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 A systematic review of the efficacy of proton pump inhibitors on refractory adult asthma. Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The efficacy and safety of adjunctive corticosteroids in the treatment of tuberculous pleurisyA systematic review and meta-analysis Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Nonclinical safety profiles of DS-1515, a novel oral PI3Kd inhibitor. Source: International Congress 2018 – Basic pharmacology Year: 2018 SPARTA: Efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018 Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003